TY - JOUR AU - Dr ravikant Verma AU - Dr Shilpa Vahikar AU - Dr Shaila Kumari Mitra AU - Dr Aakanchha Dubey AU - Dr Pushpendra Sagar AU - Dr Kanchan shrivastava AU - Dr Deval brajesh AU - Dr Dharmendra Singh PY - 2023/04/28 Y2 - 2024/03/28 TI - A study of E- Cadherin in benign and malignant breast lesions with its correlation with histopathology JF - Tropical Journal of Pathology and Microbiology JA - Trop J Pathol Microbiol VL - 9 IS - 2 SE - Original Article DO - UR - https://pathology.medresearch.in/index.php/jopm/article/view/621 AB - IntroductionBreast diseases are showing a rising trend worldwide. A number of studies have been done to show the magnitude of problem. Various breast lesions include inflammatory lesions, benign proliferative breast diseases like firoadenosis, fibrocystic disease papillomas etc. and various cancers. Much concern is given to malignant lesions of breast. Breast cancer ranks first among malignant tumors affecting female in many part of world.Aims And ObjectivesWe aimed to study correlation between histopathology and immunohistochemical analysis of E- cadherin in benign and malignant breast lesionsTo study role of E- cadherin in differentiating benign verses malignant breast lesionsSTUDY DESIGN- Cross-sectional study.SAMPLE SIZE- The present study was conducted on 100 cases of breast tumors. The study was carried out to find out the histological type of lesion along with role of E-cadherin in benign and malignant breast lesions.INCLUSION CRITERIA FOR HISTOPATHOLOGICAL EXAMINATION-Resected breast tissue specimens suspected to have benign and neoplastic lesions along with all the mastectomy specimen. EXCLUSION CRITERIA FOR HISTOPATHOLOGICAL EXAMINATIONInadequate tissue sample.Autolysed tissue sample. RESULT- Out of 100 cases studied, 22 cases were benign and 78 cases were malignant lesions. CONCLUSION- Present study demonstrates that E-cadherin is strongly expressed in all benign breast lesions and there is increasing loss of E-cadherin expression with increasing grade/severity of malignancy. ER -